Evidence map›Paper›PMID 31481394›Full record

ArticleBMJ (Clinical research ed.)2019

Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study.

Rasiah Thayakaran, Nicola J Adderley, Christopher Sainsbury, Barbara Torlinska, Kristien Boelaert, Dana Šumilo, Malcolm Price, G Neil Thomas, Konstantinos A Toulis, Krishnarajah Nirantharakumar

Open access · hybridAbstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 7 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 7 syntheses or guidelines pooled it, 136 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Approach to the Patient Considering Thyroid Hormone Deprescribing.The Journal of clinical endocrinology and metabolism · 2026
    Review
  15. Observational
  16. Measuring Hypothyroidism Disease Control Using a TSH-based "Time-in-range".The Journal of clinical endocrinology and metabolism · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Rasiah ThayakaranInstitute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Nicola J AdderleyInstitute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Christopher SainsburyInstitute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Barbara TorlinskaInstitute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Kristien BoelaertInstitute of Metabolism and Systems Research, Edgbaston, Birmingham B15 2TT, UK.
Dana ŠumiloInstitute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Malcolm PriceInstitute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
G Neil ThomasInstitute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Konstantinos A ToulisInstitute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Krishnarajah NirantharakumarInstitute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK K.Nirantharan@bham.ac.uk.ORCID https://orcid.org/0000-0002-6816-1279
University of Birmingham · GBThe Edgbaston Hospital · GB424 General Military Hospital · GRNHS Greater Glasgow and Clyde · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore whether thyroid stimulating hormone (TSH) concentration in patients with a diagnosis of hypothyroidism is associated with increased all cause mortality and a higher risk of cardiovascular disease and fractures.

designRetrospective cohort study.

settingThe Health Improvement Network (THIN), a database of electronic patient records from UK primary care.

participantsAdult patients with incident hypothyroidism from 1 January 1995 to 31 December 2017. EXPOSURE: TSH concentration in patients with hypothyroidism.

main outcome measuresIschaemic heart disease, heart failure, stroke/transient ischaemic attack, atrial fibrillation, any fractures, fragility fractures, and mortality. Longitudinal TSH measurements from diagnosis to outcomes, study end, or loss to follow-up were collected. An extended Cox proportional hazards model with TSH considered as a time varying covariate was fitted for each outcome.

results162 369 patients with hypothyroidism and 863 072 TSH measurements were included in the analysis. Compared with the reference TSH category (2-2.5 mIU/L), risk of ischaemic heart disease and heart failure increased at high TSH concentrations (>10 mIU/L) (hazard ratio 1.18 (95% confidence interval 1.02 to 1.38; P=0.03) and 1.42 (1.21 to 1.67; P<0.001), respectively). A protective effect for heart failure was seen at low TSH concentrations (hazard ratio 0.79 (0.64 to 0.99; P=0.04) for TSH <0.1 mIU/L and 0.76 (0.62 to 0.92; P=0.006) for 0.1-0.4 mIU/L). Increased mortality was observed in both the lowest and highest TSH categories (hazard ratio 1.18 (1.08 to 1.28; P<0.001), 1.29 (1.22 to 1.36; P<0.001), and 2.21 (2.07 to 2.36; P<0.001) for TSH <0.1 mIU/L, 4-10 mIU/L, and >10 mIU/L. An increase in the risk of fragility fractures was observed in patients in the highest TSH category (>10 mIU/L) (hazard ratio 1.15 (1.01 to 1.31; P=0.03)).

conclusionsIn patients with a diagnosis of hypothyroidism, no evidence was found to suggest a clinically meaningful difference in the pattern of long term health outcomes (all cause mortality, atrial fibrillation, ischaemic heart disease, heart failure, stroke/transient ischaemic attack, fractures) when TSH concentrations were within recommended normal limits. Evidence was found for adverse health outcomes when TSH concentration is outside this range, particularly above the upper reference value.

Indexed as

AdultAgedCardiovascular DiseasesFemaleFractures, BoneHumansHypothyroidismLongitudinal StudiesMaleMiddle AgedReference ValuesRetrospective StudiesRisk FactorsThyroid GlandThyrotropinThyroxineThyrotropinThyroxine

Identifiers

PMID31481394
PMCPMC6719286
OpenAlexW2971614705

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.